‹ All stocks
Enliven Therapeutics
ELVN · NASDAQ · Healthcare
$46.58
▼ $1.04 (-2.19%)
Day range
$46.34 – $47.75
Year range
$14.79 – $62.32
Open
$47.61
Previous close
$47.62
Market cap
$3.43B
Volume (24h)
$30.0K
Volume (52w)
$1.40M
Performance
7D
▼ -9.03%
1M
▲ 20.36%
3M
▼ -21.57%
6M
▲ 10.24%
1Y
▲ 114.05%
YTD
▲ 199.73%
3Y
▲ 341.91%
5Y
▲ 247.59%
All-time
▼ -22.37%
Key statistics
P/E ratio
-27.24
EPS (TTM)
$-1.71
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
73.6M
About Enliven Therapeutics
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Visit websiteCountry: United States of America
More in Healthcare
LLY Eli Lilly and Company |
$1409.16 | -1.57% |
JNJ Johnson & Johnson |
$279.32 | -1.14% |
ABBV AbbVie |
$292.49 | -0.70% |
MRK Merck & Co. |
$143.71 | -0.52% |
UNH UnitedHealth Group Incorp… |
$388.08 | -5.81% |